{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:53:00Z","timestamp":1784231580830,"version":"3.55.0"},"reference-count":42,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Cancer Aid","award":["70115384"],"award-info":[{"award-number":["70115384"]}]},{"name":"Clinician Scientist Program of Heidelberg University, Faculty of Medicine","award":["70115384"],"award-info":[{"award-number":["70115384"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Uveal melanoma represents a rare and aggressive subtype of melanoma with limited treatment options and poor prognosis, especially in the metastatic setting. Tebentafusp, a bispecific fusion protein, offers a promising therapeutic approach by targeting gp100, an antigen highly expressed in uveal melanoma cells, and redirecting T cell-mediated cytotoxicity towards tumor cells. This review provides an overview of the preclinical and clinical data on tebentafusp in the management of metastatic uveal melanoma. We summarize the mechanism of action, clinical efficacy, safety profile, and ongoing research efforts surrounding this innovative immunotherapy. Preclinical studies have demonstrated the ability of tebentafusp to induce potent and specific anti-tumor immune responses against gp100-expressing uveal melanoma cells. Clinical trials have shown encouraging results, with tebentafusp exhibiting meaningful clinical activity in a subset of patients with metastatic uveal melanoma. Importantly, tebentafusp has also demonstrated a manageable safety profile. By specifically targeting tumor cells expressing gp100, tebentafusp offers a promising therapeutic avenue for individuals with metastatic uveal melanoma, meeting a significant clinical need in this context. Continued clinical trials will provide additional insights into the impact of tebentafusp on treatment-resistant metastatic cutaneous melanoma. Furthermore, we are exploring the potential of T cell engagers directed against the cancer testis antigen PRAME, which could have widespread utility in the treatment of cutaneous melanoma as well as other PRAME-expressing malignancies.<\/jats:p>","DOI":"10.3390\/pharmaceutics16081046","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T15:24:16Z","timestamp":1722957856000},"page":"1046","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2850-2526","authenticated-orcid":false,"given":"Robin","family":"Reschke","sequence":"first","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany"},{"name":"German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H.","family":"Enk","sequence":"additional","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany"},{"name":"German Cancer Consortium (DKTK), Core Center Heidelberg, 69120 Heidelberg, Germany"},{"name":"German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10384-019-00656-9","article-title":"Clinical predictors of survival in metastatic uveal melanoma","volume":"63","author":"Lorenzo","year":"2019","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bjophthalmol-2012-302323","article-title":"MRI in the detection of hepatic metastases from high-risk uveal melanoma: A prospective study in 188 patients","volume":"97","author":"Marshall","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2217\/fon-2021-1260","article-title":"Tebentafusp for the treatment of metastatic uveal melanoma","volume":"18","author":"Hassel","year":"2022","journal-title":"Futur. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: A phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.21037\/atm.2016.05.04","article-title":"Uveal melanoma as a target for immune-therapy","volume":"4","author":"Oliva","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1358\/dot.2023.59.3.3542417","article-title":"Tebentafusp: A novel drug for the treatment of metastatic uveal melanoma","volume":"59","author":"Wang","year":"2023","journal-title":"Drugs Today"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, A TCR\/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100046","DOI":"10.1016\/j.esmoop.2020.100046","article-title":"Immune cell engagers in solid tumors: Promises and challenges of the next generation immunotherapy","volume":"6","author":"Spagnoletti","year":"2021","journal-title":"ESMO Open"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Omer, M.H., Shafqat, A., Ahmad, O., Alkattan, K., Yaqinuddin, A., and Damlaj, M. (2023). Bispecific Antibodies in Hematological Malignancies: A Scoping Review. Cancers, 15.","DOI":"10.3390\/cancers15184550"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sim\u00e3o, D.C., Zarrabi, K.K., Mendes, J.L., Luz, R., Garcia, J.A., Kelly, W.K., and Barata, P.C. (2023). Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer. Cancers, 15.","DOI":"10.3390\/cancers15051412"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17588359231160140","DOI":"10.1177\/17588359231160140","article-title":"Tebentafusp: A first-in-class treatment for metastatic uveal melanoma","volume":"15","author":"Howlett","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e432462","DOI":"10.1200\/EDBK_432462","article-title":"Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches","volume":"44","author":"Kidwai","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Reschke, R., Enk, A.H., and Hassel, J.C. (2024). Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126532"},{"key":"ref_14","first-page":"1083825","article-title":"Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction","volume":"3","author":"Rouhani","year":"2021","journal-title":"Res. Sq."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2197358","DOI":"10.1080\/2162402X.2023.2197358","article-title":"Tissue-resident memory T cells in immune-related adverse events: Friend or foe?","volume":"12","author":"Reschke","year":"2023","journal-title":"OncoImmunology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Reschke, R., Deitert, B., Enk, A.H., and Hassel, J.C. (2024). The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma\u2014Two sides of the same coin?. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1385781"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9527","DOI":"10.1200\/JCO.2021.39.15_suppl.9527","article-title":"Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator\u2019s choice (IC) in first-line metastatic uveal melanoma","volume":"39","author":"Hassel","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hassel, J.C., Stanhope, S., Greenshields-Watson, A., Machiraju, D., Enk, A., Holland, C., Abdullah, S.E., Benlahrech, A., Orloff, M., and Nathan, P. (2024). Tebentafusp induces a T cell driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action. J. Investig. Dermatol.","DOI":"10.1016\/j.jid.2024.03.048"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Reschke, R., Gussek, P., and Ziemer, M. (2021). Identifying High-Risk Tumors within AJCC Stage IB\u2013III Melanomas Using a Seven-Marker Immunohistochemical Signature. Cancers, 13.","DOI":"10.3390\/cancers13122902"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Reschke, R., Dumann, K., and Ziemer, M. (2022). Risk Stratification and Clinical Characteristics of Patients with Late Recurrence of Melanoma (>10 Years). J. Clin. Med., 11.","DOI":"10.3390\/jcm11072026"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.annonc.2023.11.013","article-title":"Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis","volume":"35","author":"Piulats","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Reiter, S., Schroeder, C., Broche, J., Sinnberg, T., Bonzheim, I., S\u00fcsskind, D., Flatz, L., and Forschner, A. (2023). Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: A case report. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1167791"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"112986","DOI":"10.1016\/j.ejca.2023.112986","article-title":"Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp","volume":"191","author":"Hassel","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e006747","DOI":"10.1136\/jitc-2023-006747","article-title":"Tebentafusp in combination with durvalumab and\/or tremelimumab in patients with metastatic cutaneous melanoma: A phase 1 study","volume":"11","author":"Hamid","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S855","DOI":"10.1016\/j.annonc.2021.08.1398","article-title":"1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma","volume":"32","author":"Salama","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S875","DOI":"10.1016\/j.annonc.2022.07.854","article-title":"728O Results from phase I dose escalation of IMC-F106C, the first PRAME \u00d7 CD3 ImmTAC bispecific protein in solid tumors","volume":"33","author":"Hamid","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1172\/JCI92335","article-title":"A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide\/HLA-I antigens","volume":"127","author":"Chang","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","article-title":"PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors","volume":"46","author":"Kaczorowski","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1167\/iovs.64.15.36","article-title":"PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma","volume":"64","author":"Gelmi","year":"2023","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2024.42.16_suppl.9507","article-title":"Phase 1 safety and efficacy of IMC-F106C, a PRAME \u00d7 CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)","volume":"42","author":"Hamid","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1182\/blood-2019-129958","article-title":"Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER\u00ae) Molecules","volume":"134","author":"Bunk","year":"2019","journal-title":"Blood"},{"key":"ref_37","unstructured":"(2024, April 25). Immatics Reports Interim Clinical Data from ACTengine\u00ae IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial|Immatics N.V. Available online: https:\/\/investors.immatics.com\/news-releases\/news-release-details\/immatics-reports-interim-clinical-data-actenginer-ima203-and\/."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"TPS9594","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9594","article-title":"A phase 2\/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM)","volume":"41","author":"Davar","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S888","DOI":"10.1016\/j.annonc.2022.07.879","article-title":"753P Targeting solid tumors with IMA402, a next-generation bispecific T cell engaging receptor against PRAME","volume":"33","author":"Missel","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","article-title":"CAR-T cells and BiTEs in solid tumors: Challenges and perspectives","volume":"14","author":"Edeline","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_41","first-page":"215","article-title":"Therapy understanding and health related quality of life in stage III\/IV melanoma patients treated with novel adjuvant therapies","volume":"19","author":"Reschke","year":"2021","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","article-title":"Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: A novel immune cocktail therapy for non-inflamed tumors","volume":"15","author":"Yi","year":"2022","journal-title":"J. Hematol. Oncol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/8\/1046\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:30:54Z","timestamp":1760110254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/8\/1046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["pharmaceutics16081046"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16081046","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]}}}